Effect of Mannitol on Postreperfusion Syndrome During Living Donor Liver Transplant

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-04

Study Completion Date

2022-12-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Postreperfusion syndrome during living liver transplants remains a serious concern for transplant anesthesiologists. This syndrome is responsible for decreases in systemic blood pressure, systemic vascular resistance, and cardiac output and can even lead to cardiac arrest. Delayed graft function and primary graft nonfunction are closely related to postreperfusion syndrome (Therefore, attenuating the syndrome during anesthesia is of great importance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact Of Timing Of Drainage Of Massive Ascites On Operative And Post-Operative Course In Living-Donor Liver Transplant Recipients. A Prospective Randomized Controlled Trial.

NCT02867293

Massive Ascites

COMPLETED NA

Purge Vs no Purge in Living Donor Liver Transplantation Recipients

NCT02540447

Ischemia Reperfusion Injury

COMPLETED NA

Intermittent Portal and Graft Purge in Living Donor Liver Transplantation

NCT02845154

Hypotension Ischemia Reperfusion Injury

UNKNOWN NA

ICU Readmission in Adult Egyptian Patients Undergoing Living Donor Liver Transplant

NCT04067739

ICU Readmission

COMPLETED

Remote Ischemic Preconditioning in Liver Transplantation

NCT02534025

Liver Transplanatation

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplant Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

mannitol group

Group Type ACTIVE_COMPARATOR

Mannitol

Intervention Type DRUG

During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg

control group

Group Type PLACEBO_COMPARATOR

0.9% normal saline

Intervention Type OTHER

the same amount of 0.9% normal saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mannitol

During the anhepatic phase, the patients in the mannitol group (30) will receive 1 g/kg

Intervention Type DRUG

0.9% normal saline

the same amount of 0.9% normal saline

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with end-stage liver disease who will undergo living donor transplantation.

Exclusion Criteria

* Patients with a history of portopulmonary hypertension.
* Hepatopulmonary syndrome.
* Cirrhotic cardiomyopathy.
* Hepatorenal syndrome types 1 and 2.

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No